- Home
- SUPN vs HRMY Comparison
SUPN vs HRMY Comparison
Compare SUPN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- HRMY
- Stock Information
- Founded
- SUPN 2005
- HRMY 2017
- Country
- SUPN United States
- HRMY United States
- Employees
- SUPN N/A
- HRMY N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- SUPN Health Care
- HRMY Health Care
- Exchange
- SUPN Nasdaq
- HRMY Nasdaq
- Market Cap
- SUPN 2.6B
- HRMY 2.1B
- IPO Year
- SUPN 2012
- HRMY 2020
- Fundamental
- Price
- SUPN $46.02
- HRMY $32.46
- Analyst Decision
- SUPN Buy
- HRMY Strong Buy
- Analyst Count
- SUPN 2
- HRMY 9
- Target Price
- SUPN $43.00
- HRMY $55.33
- AVG Volume (30 Days)
- SUPN 654.2K
- HRMY 696.1K
- Earning Date
- SUPN 11-03-2025
- HRMY 10-28-2025
- Dividend Yield
- SUPN N/A
- HRMY N/A
- EPS Growth
- SUPN 1411.53
- HRMY 58.41
- EPS
- SUPN 1.14
- HRMY 3.10
- Revenue
- SUPN $665,125,000.00
- HRMY $772,527,000.00
- Revenue This Year
- SUPN $4.84
- HRMY $20.09
- Revenue Next Year
- SUPN $17.69
- HRMY $16.86
- P/E Ratio
- SUPN $38.93
- HRMY $10.40
- Revenue Growth
- SUPN 5.55
- HRMY 17.74
- 52 Week Low
- SUPN $29.16
- HRMY $26.47
- 52 Week High
- SUPN $46.79
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- SUPN 63.81
- HRMY 33.92
- Support Level
- SUPN $43.44
- HRMY $31.61
- Resistance Level
- SUPN $46.72
- HRMY $32.84
- Average True Range (ATR)
- SUPN 1.12
- HRMY 1.16
- MACD
- SUPN -0.39
- HRMY -0.48
- Stochastic Oscillator
- SUPN 77.91
- HRMY 14.09
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.